Welcome to our dedicated page for Kalaris Therapeutics SEC filings (Ticker: KLRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kalaris Therapeutics filings document formal disclosures for a Nasdaq-listed clinical-stage biopharmaceutical company developing retinal-disease therapeutics. The record includes 8-K reports on operating and financial results, Regulation FD clinical presentations for TH103, material-event disclosures, capital-structure matters, and executive officer changes.
Proxy materials describe annual meeting and shareholder voting matters, while security disclosures identify Kalaris common stock under the KLRS ticker. Clinical disclosures focus on TH103 safety, tolerability, pharmacokinetics, early efficacy information, manufacturing updates, and the company's retinal-disease development plans.
Kalaris Therapeutics director David Hallal received a new stock option grant covering 9,000 shares of common stock. The option has an exercise price of $4.72 per share and was granted as compensation rather than a market purchase.
The option was granted on June 3, 2026 and is scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 annual stockholder meeting, conditioned on his continued service. Following this grant, Hallal holds options for 9,000 underlying shares directly.
Kalaris Therapeutics director Srinivas Akkaraju received a grant of options to buy 9,000 shares of common stock on June 3, 2026. The options have an exercise price of $4.72 per share and expire on June 2, 2036. The underlying 9,000 shares are scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 Annual Meeting of Stockholders, subject to continued service. After this grant, the filing shows Akkaraju holding 9,000 stock options directly.
Kalaris Therapeutics, Inc. director Michael Dybbs received a grant of stock options representing 9,000 shares of Common Stock. The options have an exercise price of $4.72 per share and expire on June 2, 2036.
The shares underlying the option are scheduled to vest in full on the earlier of June 3, 2027 or the date of Kalaris Therapeutics' 2027 Annual Meeting of Stockholders, provided he continues to serve the company through that time. Following this grant, he holds 9,000 derivative securities directly.
Kalaris Therapeutics director Anthony P. Adamis received a new stock option grant covering 9,000 shares of common stock. The option has an exercise price of $4.72 per share and expires on June 2, 2036.
The shares underlying the option are scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 annual meeting of stockholders, subject to continued service. Following this grant, Adamis holds 9,000 derivative securities linked to common stock directly.
Kalaris Therapeutics director Leone D. Patterson received a new stock option grant covering 9,000 shares of common stock. The option has an exercise price of $4.72 per share and increases her directly held option position to 9,000 shares. The award was granted on June 3, 2026 and is scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 annual stockholder meeting, as long as she continues in service.
Kalaris Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 3, 2026. Stockholders elected directors Napoleone Ferrara, M.D., David Hallal, and Leone Patterson, with each receiving more than 15.6 million votes in favor and roughly 0.5–0.7 million votes withheld.
Stockholders cast an advisory vote on executive compensation and a separate advisory vote on how often to hold future executive compensation votes. A large majority, with 16,336,117 votes, supported holding this advisory vote every year. After reviewing these results, the Board of Directors plans to conduct future advisory votes on named executive officer pay annually. Another proposal received 19,771,260 votes for, 1,583 against, and 601 abstentions.
Kalaris Therapeutics’ major shareholder group tied to Samsara BioCapital has updated its Schedule 13D, reporting a controlling stake in the company’s common stock. Dr. Srinivas Akkaraju is deemed to beneficially own 12,900,583 shares, representing 54.2% of the 23,792,278 shares outstanding as of May 5, 2026.
The filing details that on May 20, 2026, Samsara Opportunity Fund bought 244,300 shares from Samsara BioCapital, L.P. in a private sale at $4.83 per share, for a total of $1,179,969, funded with partner capital. Samsara LP also made a pro rata in-kind distribution of 66,906 shares, reallocating holdings among affiliated entities.
Kalaris Therapeutics, Inc. reported an insider group transaction where an affiliated investment vehicle, Samsara Opportunity Fund, L.P., bought 244,300 shares of common stock at $4.83 per share in a privately negotiated deal with Samsara BioCapital, L.P.
The filing also records several non-market, pro rata in-kind distributions among related Samsara entities, reallocating a total of 86,314 shares of Kalaris common stock internally. Following the purchase, Samsara Opportunity Fund, L.P. holds 2,224,147 Kalaris shares indirectly associated with director and ten percent owner Dr. Srinivas Akkaraju.
Kalaris Therapeutics reported a net loss of $10.9 million for the quarter ended March 31, 2026, slightly wider than the $10.2 million loss a year earlier. Operating expenses rose to $11.8 million, driven mainly by higher research and development spending of $7.6 million as the company advances its lead retinal drug candidate TH103.
General and administrative costs were stable at $4.3 million. Other income of $1.0 million partially offset the operating loss. Kalaris ended the quarter with $104.9 million in cash, cash equivalents and marketable securities and total assets of $109.8 million, against total liabilities of $41.2 million, including a $32.1 million royalty obligation to its majority stockholder Samsara BioCapital.
Net cash used in operating activities was $11.6 million, and the company shifted $70.4 million into U.S. Treasury marketable securities. Management believes existing liquidity will fund operating and capital needs for at least 12 months from the financial statement issuance date while it continues developing TH103 for retinal diseases.
Kalaris Therapeutics reported first‑quarter 2026 results and highlighted progress in its retinal disease program TH103. As of March 31, 2026, the company held $104.9 million in cash, cash equivalents and marketable securities and expects this to fund operations into the fourth quarter of 2027 and through key clinical milestones.
Research and development expenses rose to $7.6 million from $6.0 million a year earlier as additional clinical sites were opened and patients enrolled. General and administrative expenses were stable at $4.3 million. Net loss was $10.9 million, compared with $10.2 million in the prior‑year quarter, with no revenue reported.
The company has begun patient screening in its Phase 1b/2 trial of TH103 for neovascular age‑related macular degeneration and has manufactured new clinical material for upcoming dosing. It anticipates preliminary Phase 1b/2 data in the first half of 2027 and continues to plan Phase 3 trials targeted for initiation by year‑end 2027.